Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?

Bastiaan SolJeroen M K de FiletteGil AwadaSteven P M J RaeymaeckersSandrine AspeslaghC E AndreescuBart NeynsBrigitte Velkeniers

Published in: European journal of endocrinology (2020)

ICI therapy could be a promising treatment option for pituitary carcinoma, considering the mechanisms of TMZ-induced hypermutation with increased immunogenicity, pituitary expression of CTLA-4 and PD-L1, and the frequent occurrence of hypophysitis as a side effect of ICI therapy.

Keyphrases

poor prognosis
risk assessment
stem cells
growth hormone
oxidative stress
high glucose
replacement therapy
binding protein
drug induced